Clinical, environmental, and genetic risk measures show modest ability to distinguish between individuals for alcohol, drug, and any substance use disorders in young adulthood. The predictive power of ...
In this video interview, Raj Indupuri, CEO and co-founder of eClinical Solutions, explains why organizations that build ...
Unveiling the pathologic predictor in patients with metastatic hormone-sensitive prostate cancer treated with abiraterone: Intraductal carcinoma of the prostate and its subtypes. This is an ASCO ...
Although patients with inflammatory bowel disease (IBD) may have genetic predispositions to develop such diseases, this alone does not appear to be sufficient for the onset of inflammation. An ...
These tensions are not transient. They are pushing organizations to rethink their planning practices, operating models, ...
TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer. Background: Although PCa incidence has stabilized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results